Bibliography
- ROTHWELL PM, COULL AJ, SILVER LE et al.: Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet (2005) 366(9499):1773-1783.
- GONGORA-RIVERA F, LABREUCHE J, JARAMILO A, STEG PG, HAUW J-J, AMARENCO P: The prevalence of coronary atherosclerosis in patients with stroke. Stroke (2007) 38:1203-1210.
- DHAMOON MS, SCIACCA RR, RUNDEK T, SACCO RL, ELKIND MS: Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. Neurology (2006) 66(5):641-646.
- SACCO RL, BENJAMIN EJ, BRODERICK JP et al.: American heart association prevention conference. IV. Prevention and rehabilitation of stroke. Risk Factors Stroke (1997) 28(7):1507-1517.
- MACMAHON S: Blood pressure and the prevention of stroke. J. Hypertens. (1996) 14(S6):39-46.
- AMARENCO P, LAVALLÉE P, TOUBOUL P-J: Stroke prevention, blood cholesterol, and statins. Lancet Neurol. (2004) 3:271-278.
- AMARENCO P: The effects of statins in stroke prevention. Curr. Opin. Lipidol. (2005) 16:614-618.
- AMARENCO P, LABREUCHE J, LAVALLEE P et al.: Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke (2004) 35:2902-2909.
- BAIGENT C, KEECH A, KEARNEY PM et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 366:1267-1278.
- LAROSA JC, GRUNDY SM, WATERS DD et al.: For the treating to new target (TNT) investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. (2005) 352.
- COLHOUN HM, BETTERIDGE DJ, DURRINGTON PN et al.: Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet (2004) 364:685-696.
- SEVER PS, DAHLOF B, POULTER NR et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial – lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet (2003) 361:1149-1158.
- HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet (2003) 361:2005-2016.
- SCHWARTZ GG, OLSSON AG, EZEKOWITZ MD et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA (2001) 285:1711-1718.
- WATERS DD, SCHWARTZ GG, OLSSON AG et al.: Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction. Circulation (2002) 106:1690-1695.
- ATHYROS VG, PAPAGEORGIOU AA, MERCOURIS BR et al.: Treatment with atorvastatin to the National cholesterol educational program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek atorvastatin and coronary-heart-disease evaluation (GREACE) study. Curr. Med. Res. Opin. (2002) 18:220-228.
- KNOPP RH, D'EMDEN M, SMILDE JG, POCOCK SJ; ON BEHALF OF THE ASPEN STUDY GROUP: Efficacy and safety of atorvastatin in the prevention of cardiovascular endpoints in subjects with Type 2 diabetes. Diabetes Care (2006) 29:1478-1485.
- WANNER C, KRANE V, MARZ W et al.; FOR THE GERMAN DIABETES AND DIALYSIS STUDY INVESTIGATORS: Atorvastatin in patients with Type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. (2005) 353:238-248.
- CANNON CP, BRAUNWALD E, MCCABE CH et al.; PRAVASTATIN OR ATORVASTATIN EVALUATION AND INFECTION THERAPY-THROMBOLYSIS IN MYOCARDIAL INFARCTION 22 INVESTIGATORS: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. (2004) 350(15):1495-1504.
- WATERS DD, LAROSA JC, BARTER P et al.: Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J. Am. Coll. Cardiol. (2006) 48(9):1793-1799.
- PEDERSEN TR, FAERGEMAN O, KASTELEIN JJP et al.: High-dose atoravastatin versus usual-dose simvastatin for secondary preventin after myocardial infatcion. The IDEAL study: a randomized controlled trial. JAMA (2005) 294:2427-2445.
- KOREN MJ, HUNNINGHAKE DB; ON BEHALF OF THE ALLIANCE INVESTIGATORS: Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics. The ALLIANCE study. J. Am. Coll. Cardiol. (2004) 44:1772-1779.
- HEART PROTECTION STUDY COLLABORATIVE GROUP: Effect of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet (2004) 363:757-767.
- AMARENCO P, BOGOUSSLAVSKY J, CALLAHAN A III et al.; FOR THE SPARCL INVESTIGATORS: High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. (2006) 355(6):549-555.
- AMARENCO P, GOLDSTEIN LB, SZAREK M et al.; FOR THE SPARCL INVESTIGATORS: Effects of intense LDL-C reduction in patients with stroke or transient ischemic attack: the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial. Stroke (2007) 38:(In Press).
- GOLDSTEIN LB, AMARENCO P, SZAREK M et al.: Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study. Neurology (2007) (In Press).
- DE LEMOS JA, BLAZING MA, WIVIOTT SD et al.; FOR THE A TO Z INVESTIGATORS: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z trial. JAMA (2004) 292:1307-1316.
- MAZIGHI M, LAVALLÉE PC, LABREUCHE J, AMARENCO P: Statin in stroke prevention: what is known, what is new and what is next? Curr. Opin. Lipidol. (2007) (In Press).